Clinical trial
Phase 2 Study on Use of a Combination of Pemetrexed in Patients With Advanced…
NCT00190801 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00190801 |
|---|---|
| Title | Phase 2 Study on Use of a Combination of Pemetrexed in Patients With Advanced Gastric Carcinoma |
| Official title | Open-Label Single-Arm Phase 2 Study of ALIMTA Plus Cisplatin in Korean Patients With Advanced Gastric Carcinoma |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastrointestinal Neoplasms |
| Intervention type | Drug |
| Interventions | pemetrexed, cisplatin |
| Enrollment | 50 |
| Start date | Sep 1, 2003 |
| Completion | Sep 1, 2005 |
| First posted | Sep 19, 2005 |
| Last update posted | Jan 26, 2007 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: